Financial giants have made a conspicuous bullish move on Capricor Therapeutics. Our analysis of options history for Capricor Therapeutics CAPR revealed 11 unusual trades.
Delving into the details, we found 54% of traders were bullish, while 36% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $68,170, and 9 were calls, valued at $673,600.
- Massive Demand & Disruptive Potential – Boxabl has received interest for over 190,000 homes, positioning itself as a major disruptor in the housing market.
- Revolutionary Manufacturing Approach – Inspired by Henry Ford’s assembly line, Boxabl’s foldable tiny homes are designed for high-efficiency production, making homeownership more accessible.
- Affordable Investment Opportunity – With homes priced at $60,000, Boxabl is raising $1 billion to scale production, offering investors a chance to own a stake in its growth.
Predicted Price Range
After evaluating the trading volumes and Open Interest, it’s evident that the major market movers are focusing on a price band between $5.0 and $20.0 for Capricor Therapeutics, spanning the last three months.
Volume & Open Interest Trends
In today’s trading context, the average open interest for options of Capricor Therapeutics stands at 520.67, with a total volume reaching 4,570.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Capricor Therapeutics, situated within the strike price corridor from $5.0 to $20.0, throughout the last 30 days.
Capricor Therapeutics Option Activity Analysis: Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CAPR | CALL | TRADE | BEARISH | 12/19/25 | $9.7 | $9.4 | $9.4 | $5.00 | $94.0K | 1.5K | 900 |
| CAPR | CALL | TRADE | BEARISH | 12/19/25 | $9.7 | $9.4 | $9.4 | $5.00 | $94.0K | 1.5K | 900 |
| CAPR | CALL | TRADE | BULLISH | 12/19/25 | $9.5 | $8.6 | $9.4 | $5.00 | $94.0K | 1.5K | 800 |
| CAPR | CALL | TRADE | BULLISH | 12/19/25 | $9.6 | $8.6 | $9.4 | $5.00 | $94.0K | 1.5K | 700 |
| CAPR | CALL | TRADE | BULLISH | 12/19/25 | $9.6 | $8.6 | $9.4 | $5.00 | $94.0K | 1.5K | 500 |
About Capricor Therapeutics
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company’s product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Having examined the options trading patterns of Capricor Therapeutics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Present Market Standing of Capricor Therapeutics
- With a volume of 1,116,123, the price of CAPR is up 2.91% at $13.77.
- RSI indicators hint that the underlying stock may be overbought.
- Next earnings are expected to be released in 57 days.
Professional Analyst Ratings for Capricor Therapeutics
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $30.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge’s Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.
* An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $30.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Capricor Therapeutics, Benzinga Pro gives you real-time options trades alerts.